Department of Health and Human Services March 9, 2022 – Federal Register Recent Federal Regulation Documents

Notice of Meeting
Document Number: 2022-04910
Type: Notice
Date: 2022-03-09
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting
Document Number: 2022-04943
Type: Notice
Date: 2022-03-09
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
Document Number: 2022-04942
Type: Notice
Date: 2022-03-09
Agency: Department of Health and Human Services, National Institutes of Health
Submission for OMB Review; Prevention Services Data Collection (OMB #0970-0529)
Document Number: 2022-04939
Type: Notice
Date: 2022-03-09
Agency: Department of Health and Human Services, Administration for Children and Families
The Administration for Children and Families (ACF), Children's Bureau is requesting a 3-year extension of the Prevention Services Data Collection (OMB #0970-0529, expiration 7/31/2022). There are no changes requested to the form.
Vaccines Federal Implementation Plan, Request for Comments; Correction
Document Number: 2022-04937
Type: Notice
Date: 2022-03-09
Agency: Department of Health and Human Services
The Office of the Assistant Secretary for Health published a document in the Federal Register of March 2, 2022, announcing the request for comments for the Vaccines Federal Implementation Plan. The document includes a weblink where the Vaccines Federal Implementation Plan can be found: https://www.hhs.gov/vaccines/vaccines-national- strategic-plan/vaccines-federal-implementation-plan/ index.html#:~:text=The%20Vaccines%20Federal%20Implementation% 20Plan%20ou tlines%20specific%20actions%20that%20federal,National%20Strat egic%20Plan %202021%2D2025.&text=The%20public%20comment%20period%20for,2% 2C%202022%2 0at%209%20a.m.
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2022-04984
Type: Notice
Date: 2022-03-09
Agency: Department of Health and Human Services, National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Meeting
Document Number: 2022-04982
Type: Notice
Date: 2022-03-09
Agency: Department of Health and Human Services, National Institutes of Health
Agency Information Collection Activities: Proposed Collection: Public Comment Request Medicare Rural Hospital Flexibility Program Performance, OMB No. 0915-0363-Revision
Document Number: 2022-04980
Type: Notice
Date: 2022-03-09
Agency: Department of Health and Human Services, Health Resources and Services Administration
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
Food and Drug Administration Quality Metrics Reporting Program; Establishment of a Public Docket; Request for Comments
Document Number: 2022-04972
Type: Notice
Date: 2022-03-09
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the establishment of a docket to solicit comments on changes to FDA's previously proposed quality metrics reporting program (QM Reporting Program). This notice describes considerations for refining the QM Reporting Program based on lessons learned from two pilot programs with industry that were announced in the Federal Register in June 2018, a Site Visit Program and a Quality Metrics Feedback Program, as well as stakeholder feedback on FDA's 2016 revised draft guidance for industry entitled ``Submission of Quality Metrics Data.'' FDA is interested in responses to the questions listed in section III of this document, in addition to any general comments on the proposed direction for the program. This notice is not intended to communicate our regulatory expectations for reporting quality metrics data to FDA but is instead intended to seek input from industry to inform the future regulatory approach.
Drugs for Human Use; Drug Efficacy Study Implementation; Potassium Aminobenzoate Oral Preparations; Withdrawal of Hearing Request; Withdrawal of New Drug Application; Final Resolution of Drug Efficacy Study Implementation
Document Number: 2022-04971
Type: Notice
Date: 2022-03-09
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing that all outstanding hearing requests regarding POTABA (potassium aminobenzoate) Tablets, Capsules, Powder, and Envules under Docket No. FDA-1977-N-0015 (formerly 77N-0187) (this Drug Efficacy Study Implementation (DESI) 7663) have been withdrawn. Therefore, as proposed in the notice of opportunity for hearing (NOOH), FDA finds that the products subject to the application identified in this docket, or any identical, related, or similar (IRS) products, have not been shown to be effective for use under the conditions of use prescribed, recommended, or suggested in the labeling, and hereby withdraws approval of the application under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.